Alzheon Revives Failed Alzheimer's Drug With Genetic Subtype Approach
This article was originally published in The Pink Sheet Daily
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
You may also be interested in...
Companies focused on Alzheimer's R&D need to catch up on patient involvement, and earlier diagnosis may help, patient advocate suggests.
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
Martin Tolar, a neurologist and neuroscientist by training and longtime AD R&D leader and dealmaker, believes that tramiprosate, a red-algae derivative that failed Phase III trials in 2007, had, in fact, significant disease-modifying benefit for a specific subset, but still a majority, of patients in the study. He founded Alzheon Inc. around a prodrug of tramiprosate and related intellectual property to pursue what he sees as a high-speed, low-cost pathway to test whether trampirosate could become the first approved AD drug in more than a decade – and the first personalized to a genetically identifiable patient population.